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ICAM- peptides mediate lymphocyte adhesion by binding to 
CIX I a/CD 18 and CD49d/CD29 integrins 
Rcecivrd 4 February 1991 
Three RtIren~amlno-acid palypp~idcs designated pcptidcs I, 2 and 3 wcrc synlhcsiscd us likely candidales for mimicking the role BP ICAM- as 
a Jigand. The ability of’cach peptide lo bind lymphoid cells was resrcd. Pcpride 2 largely mrdivfed cell utrachmcnf ~Punstimulaced cells and this 
binding ~11s only marginally increased by stimulntiny the cells wifh pherbni dibutyralc (P(Bu)&, Peptide 3 mediated minimal rpanrsnreur epll PI- 
utchmcnt, but this binding was significantly enkanccd fallowinp P(Bu), stimulrrian, Peptide 1 had no cR’cct an cell u(taehmcnr with or without 
stimulation. The GCII artnehmen! to pcptidc 2 was both temperature- and cation-dependent. Sludics using speifie monaelanal antibodies shaqed 
that with unsrimuhlted cells, anti-VL&4a(CD49d) or @ chain (CD29) antibodies (KD4-I 3 and 4f34) and unriCDI8 (IB4) caeh partially inhibited 
the cell binding. Manaclanal antibodies against CD54 (lCAM.1; 84Hl6 or LB2). MHC class I (WO32) and central mausc IgG had no cil’cct, 
When nntXD29 nnd anti-CD18 monoclonal antibadics were used concurrently, there was almost eomplctc inhibition of the cell attachment. These 
observations indicated that cell adhesion via ICAM- is mediated: (i) prcdomimmtly by pepride 2 in unslimulatcd and P(Bu)~~s~imulrrcci’ cells, 
and also. to some extent, by pcptidc 3 in P(Bu),-sdmulutcd cells and (ii) by binding to bath CD1 I/CD18 and CD49dlCD29 intcgrins. 
Cell adhesion: Integrin; CDI la/CDIB; CD49d/CD29: Phorbal ester; Cell attachment rtssny; Monoclonal untibady; ICAM- 
1. INTRODUCTION 
ICAM-l(CD54) is a cell surface adhesion molecule 
member of the immunoglobulin superfamily (1,21. This 
molecule is found on many cell types and its expression 
on vascular endothelium is strongly up-regulated by the 
inflammatory cytokines such as; interlcukin-1 (IL-l), 
tumor necrosis factor (;Y (TNF-CY) and interferon y (IFN- 
y) both in vitro and in vivo [3]. Its receptor is 
CD1 1 a/CD 18, one of a trio of heterodimeric molecules 
known as the p2 integrins or the CDll/CDl’! 
molecules. 
Although the CD1 la/CDl&CD54 pathway plays an 
important role in lymphocyte adhesion to entothelial 
cells, monoclonal antibodies that block CD1 la/CD18 
only partially inhibit this adhesion [4,5]. This and 
several other lines of evidence have suggested the ex- 
istence of a second CD1 la/CD18 ligand. Nomotypic 
adhesion of one cell line was inhibited by a monoclonal 
antibody to CD1 la/CD 18 but not by one to ICAM- 
[6]. In addition, there also exists a CD1 ln/CDl$-de- 
pendent, ICAM-l-independent pathway of adhesion to 
endothelial cells (41 and there are some types of target 
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cells in which CD 1 la/CD 18 dependent T-lymphocyte 
adhesion and lysis are independent of CDS4 [7), Fur- 
thermoee, in patients with a genetic deficiency of CD18 
and henceof CD1 la/CDlg, lymphocyte recruitment in- 
to inflammatory sites is aparently normal, despite pro- 
found defects in recruitment of phagocytic ells 181, in- 
dicative of an as yet uncharacterised lymphocyte migra- 
tion pathway in vivo and in vitro. Recently, an alter- 
native CD1 la/CDlg-CD54-independent leukocyte 
homotypic adhesion pathway mediated through 
CD49dED29 has been defined [9]. 
A putative second ligand is designated ICAM-2. 
cDNA sequencing has indicated that ICAM- is an in- 
tegral membrane protein with two immunoglobulin-like 
domains, whereas ICAM- has five such domains 
[1,2,10]. ICAM- and ICAM- are more closely related 
to each other (there being 34% homology between the 
two most N-terminal domains of ICAM- and 
ICAM-2) than to the other members of the im- 
munoglobulin superfamily, demonstrating the existence 
of a sub-family of immunoglobulin-like ligands that 
bind the same integrin receptor. Significantly, the 
CD1 la/CD18 binding region of ICAM- has been map- 
ped to domains 1 and 2 by domain deletion and 
systematic amino acid substitution, thus the homology 
is both structural and functional [ll]. 
The differences between ICAIVI-1 and ICAM- may 
be of potential functional importance. ICAM-I is in- 
ducible on most cell lines using cytokines, whereas 
dilkrenecs kwy be Important, Theihr& additional do- 
mains an CiX4 arc expwed to prajeft it9 
fXI1 la/CD18 binding site further from thr cell surface 
than that of ICAMa2, sq$erring that closer cell-cell 
contact would be required to effect CD1 la/CDlg-1 
ICAM- contact than the CDllst/ClX8/ICAM-I [II]. 
The binding of CDS4 to CD1 la/CDI$, a @2 integrin, 
is temperature- and cation-dependent [If]. It has also 
been shown that the 82 integrins are not involved in 
binding of Jurkat or Ramos cells to cytokine-activated 
human umbilical vascular endothelial cells (HUYEC) as 
assessed by the inability of a CD18 monoclonal an- 
tibody (60.3) to inhibit the intercellular adhesion [9]. 
CD49dKD29, on lymphoid cells, and VCAM-I, 
another member of the immunoglobulin superfamily 
similar to CDS4 and expressed by endothelial cells, 
mediate this adhesion [13]. Interestingly, it has been 
reported that high levels of CD29, the PI subunit shared 
by the VLA group of integrins are characteristic of a 
subset of lymphocytes enriched in chronic inflam- 
matory sites such as the synovia of patients with 
rheumatoid arthritis patients [14,15]. In the present 
study, the ability of the synthetic peptides which were 
predicted from the nucleotide sequence and based on 
hydrophobicity, to mimic the function of ICAM- were 
studied to identify which specific regions were involved 
IQ tlr#lns 
A lymphablaataid I&XII llnc (.bCl,) rullcd NAD lfI wag udzd in thlr 
a5sr\y. Immim0llucrrenncr fltlw rrtcrmcfry arutllas dtimanrrratcd rher
CRI I u/CL? I8 wnd 6DJYdiCB39 are exprnml on 90 rind 70% al ~hc 
dl~, rrrpcorlvcrly tdalR nal &awn). Callri wrfe ypllr enc cffiy priar 10 
It\* rtay d rrmy, hRSYCJ1P& walwct wicc whh PBS and eounrcd< 
firer ware rhcn rerurpendcvl in RPM! m&urn (0,5 t( IW’ml) cenrain. 
ing BSA (0.1% w/v). The cell suspension (2 ml) was then aliquarrrd 
lnru tube% or added to ~hc coated pIare which had been cqrtllibrrting 
111 RPM1 medium cslntninina &%A (0.2% v&l. “Phi! plats wax ins 
cubatcd at 37*C fop I I\. - 
Al the end al whir incubatian, the plate WHX washed 4 limes first 
with RPM1 containing 0.2% BJA, and then wlrh PRI. The cells 81, 
tnflred werr obxarvod under the microscope and then fixed by adding 
3% (w/v) paraformrldrhydc for approximately IS mln, Filtered 
Taluldine blue dye (Merck, 0.5% w/v In 3.7% v/v formaldehyde) \VRX 
added for a minimum of I h RI room temperature. The plarc wns then 
rvextrrd with copious amounts, of distilled water. The attachd cells 
cnn now bc counled by observing. throuph the microxcopr or qusn. 
tified in a microplate render at 690 nm by first releasing the blue dye 
by lysins the cells with 2% (w/v) SDS [ 161, 
In nnather experimcnr, the cells were treated with 4 /%phorbol 
12,13~dibutyrate (P(Uu)r) (Sigma) dixxolvcd in dimethyl su1foxidc (60 
nM final concentration) far IO min. After this time, the 
P(Ru)z.trcatcd and non-treated cclla were added to rhc place and the 
experiment repeated as above, The inhibition experiments were per- 
formed by adding the monoclonal antibodies (10 pg/ml) IP the cells 
in a tube and incubating for ten minutes at 37*C nnd then performing 
the cell attachment LCJI in the same manner as above. 
2.4. Specificity of rlrc assoy 
The specificity af ICAM- pcptidc-cell adhesion was studied for 
that both domains of ICAM- can mediate adhesion, 
in this particular cell-cell adhesion. The data suggest 
though domain 2 appears to be more relevant. Domain 
1 seems to mediate adhesion following cell activation. 
Furthermore, the results how that ICAM- peptidcs in- 
teract not only with CDllaKDlg, but also with 
CD49dKD29. 
cation-dependence using 10 mM EDTA (Kcbo, Stockhotm) and 
temperature rcquirenrent by incubations at 37 or 4OC. Furthermore 
inhibition of adhesion was tested in the continuous prcscncc of 
monoclonal antibodies directed against several well-defined adhesion 
receplors, 
3. RESULTS AND DISCUSSION 
2. MATERIALS AND METHODS 
2, I , /CA M-2 peprides 
Three fifteen-amino-acid polypcptides were synthcsiscd and 
purified to 99% purity by Pcptidc and Protein Research (PPR), 
University of Reading, UK. Peptide binding to plates was measured 
by monoclonal antibodies. 
2.2 Monoclonal antibodies 
Monoclonal antibody 4B4 (CD29) and control mouse IgG, both 
purified IgG were purchased from Coulter Immunology, Luton, UK. 
Monoclonal antibody IB4 (CDt8) was kindly provided by Dr S. 
Wright (Rockefeller Univ., NY). Monoclonal antibody W6/32 (MHC 
class 1) was used as ascites fluid and purchased from Sera Lab (Lon- 
don, UK). KD4-13 (antXD49d or anti-VLA-4a) and 84HI0 (anti- 
ICAM-I) were kindly provided by S. Shaw (NIH, Bethesda, MD). 
predictions as likely candidates for antigenisity to raise 
antibodies for functional and structural studies of 
ICAM-2. The peptides hown in Fig. 1 are designated 
peptide 1,2 and 3. The sequences indicate similarity be- 
tween peptides 2 and 3. In studies of the mixed lym- 
phocyte reaction, peptides 1 and 3 singly or in combina- 
tion inhibited. Peptide 2, in contrast, enhanced this 
reaction. Furthermore. the inhibitory role of oct%ides 1
and 3 was always abrdgated in the iresence of ‘peptide 
2 (R.S. and M.W.M., manuscript in preparation). 
These results suggested functional differences in the 
three peptides. 
Three peptides were selected based on computer 
2.3 Cell struchnrenr test 
The peptides were reconstituted in the coating buffer at a IO m&ml 
concentrationand used finally, at (100~1; 30&well) by adding to the 
ELlSA plates (Maxisorb, NU~IC, Germany) which were incubaied at 
room temperature ov rnight. At the end of the incubation, the pep- 
tide solution was shaken out and the plate was washed once with PBS 
(100 fil/wellI. Blocking solution containing human serum albumin 
(USA) (0.2% w/v) in PBS was then added (1OOpl/wcll) to saturate the 
unbound sites and incubated for 2 hat room temperature. At the end 
To further elucidate the roles of the peptides they 
were tested in a cell adhesion assay. The results in 
Fig. 2a show that peptide 2 mediates most of the cell 
binding. However when cells are treated with P(Bu)2, 
the adhesion mediated by peptide 3 was significantly in- 
creased. Bhorbol esters are known to induce 
CD1 l/CD1 g-dependent leukocyte adhesion [l?‘]. Pep- 
tide 1 did not mediate adhesion whether the cells are un- 
treated or P(Bu)z-treated.,The data suggest that a major 
adhesion binding site on ICAM- is located on peptide 
Fig* I o The nmiw rteid rcqucweaof the three peptittcu urcd in thr cell 
nltachmmr way. Thcrr ix a ximilarity bctwccn pcptidcs 2 and 3. This 
similarity may indisrtr the probable binding xite. 
2 which is found on the second immunoglobulin-like 
domain. When cells are activated with P(Bu)z, cell at= 
tachment can be mcdiatcd to some extent by peptide 3 
which is located on domain one of the ICAM- 
molecule. Thus there are two independent adhesion 
mediating sites, located on the two domains which ap- 
pear to function depending on the activation status of 
the adhering cell. Polyscra that bound peptide 1 failed 
to inhibit in the cell aggregation assay, confirming that 
this peptide has no role in adhesion (unpublished ata) 
and was therefore used as a control in the present study. 
The specificity of adhesion was studied for both 
temperature and cation-dependence. The results in 
Fig. 2b show that EDTA inhibited adhesion. Further- 
more adhesion occurred only at 3*/‘C and was com- 
pletely abolished at 4°C. Both features arc charac- 
teristic of integrin-receptor mediated adhesion [12,171, 
To test the integrins involved in this cell attachment 
a panel of monoclonal antibodies against various cell 
surface molecules was tested. We expected that anti- 
CD18 mab would completely inhibit the cell attachment 
since ICAM- is a known ligand for CD1 la/CD18 [lo]. 
The latter molecule is the major 02 integrin of NAD-20 
cells (only 2% and 2.7% of the cells express 
CDllbICD18 and CDllc/CD18, respectively [18]). 
However, the results in Fig. 3 show that anti-CD18 
always partially inhibited. Anti-CD29 also partially in- 
hibited. Furthermore, anti-VLri-4cr mab inhibited to 
the same extent as the anti-CD29 mab. The combina- 
tion of both anti-CD18 and anti-CD29 aimost com- 
pletely inhibited adhesion. Mabs against other cell sur- 
face molecules uch as CD54 (ICAM-1) and MHC Class 
I were not inhibitory. This observation suggests that 
D 
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Fig. 2. (a) The binding of ~hc lymphoblastoid NAD-2O cells to.rhc 
various iCAM- peptidcs. (b) The effect of EDTA nnd rcmpcraturc 
on cdl sttnchmcnr to pcptidc 2. Pcptitlc 1 was wed as the negative 
control. 
adhesion mediated by peptide 2 is not only via binding 
to the CD1 la/CD18 molecule but atso to the 
CD49dICD29 (VLA-4) molecule. Therefore the ligand 
ICAM- uses two integrin receptors to mediate adhe- 
sion. 
Fig. 3. The inhibition of cell binding to peptide 2 by a panel of an- 
tibodies. MlgG is mouse immunoglobulin. 
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Several liner of evidence have $uy(#etred the cxkrencs: 
oP a second CD1 lst/CD1&? ligand derignnred IChM4. 
This ligand was cloned, and sequencing indieatcd an in- 
tegral- membrane protein with two immunoglobulin-like 
domains [lo]. Recently, antibodies to recombinant 
ICAM- have confirmed that native ICAM- ia a cell 
surftree glycoprorein with an apparent MW of 55 088 
expressed by slaseular endothelium and some leukocytes 
[19J. To date, its functional role in antigen-spxifie T- 
cell recognition remains posrly defined. We have used 
a novel approach of using the synthetic peptides, 
predicted from its cBNA sequence, to mimic its func- 
tional roie as a ligund in order to identify the sites In- 
volved in cell adhesion. 
The results indicate that ICAM- has a minimum of 
two binding sites located on each of the two immuno- 
globulin-like domains, A major adhesion site for cells is 
on domain 2 since it accounts for most of the binding of 
unstimulated and P(Bu)a.stimulated cells. Wit.h cell ac- 
tivation following P(Bu)2, domain 1 also mediates 
adhesion. Peptides 2 mediates adhesion by interacting 
with CD1 la/CD18 which is expected since ICAM- was 
identified in this way. The finding that the peptidc also 
interacts with CD49dKD29 is novel and may be due to 
structural homology between ICAM- and VCAM-I, 
since both molecules are members of the immuno- 
globulin stiwrfamily. 
The binding of the integrin receptors to the peptide 
seems to be an active cellular process. We have found 
that binding of cells to ICAM- peptides via CD49d/ 
CD29 and CD1 la/CD18 molecules is a temperature- 
sensitive and cation-dependent process, consistent with 
the interaction of ICAM- with an integrin-like 
receptor. 
CD49d/CD29 and CD49eKD29 integrins both bind 
to fibronectin (FN) [20,21], and CD49d/CD29 also 
recognises a sequence on FN which has previously been 
shown to be recognised by a variety of neural crest cells 
[22,23]. Recently CDS4 has been shown to be a ligand 
for both CD1 la/CDlg and CD1 lb/CDlg [24], There 
are striking similarities between CD1 la/CD18 and 
CDrlBd/CD2%integrins. The cell binding is enhanced in 
both by P(Bu)a treatment. Increased binding is not ac- 
companied by increased cell surface expression of the 
receptors but by a change in receptor affinity for the 
ligand. The significance of the differential usage of the 
same ligand by two integrin receptors remains unclear 
but is consistent with the promiscuous nature of in- 
tegrin receptors and the functional diversity which is 
necessary in this recognition system. 
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